In oncology therapeutic development and clinical intervention, partial responses and relapse are common phenomena and a significant impediment to effective treatments for patients. As our understanding of the complex biology of cancers continues to increase, we know that a significant contributor to these effects lies in cancers harboring a diverse collection of cells with distinct and dynamic molecular profiles. This feature of cancer heterogeneity manifests in several ways: intra- and inter-tumor, intra-cellular, as well as spatial and temporal differences.
With the advent of single-cell genomic technologies, we can now interrogate cancer heterogeneity at a more fundamental level to enable more informed and potentially effective therapeutic strategies in clinical development. In this webinar, featured speakers will discuss a specific platform capable of detecting genomic content from individual cells, thereby providing insights into cancer heterogeneity and response to specific therapeutics.
This webinar is part of a scientific series Covance is offering focused on trends, opportunities and challenges associated with current and future applications in oncology. Learn more and register for upcoming webinars on topics such as adoptive T-cell therapies, biomarker technologies for the detection of rare cancer driver mutations and novel targeted therapies, and more.
Steve Anderson, PhD, Chief Scientific Officer, Covance Drug Development
Steven Anderson is senior vice president and chief scientific officer for Covance Drug Development. He has worked for LabCorp for 30 years and has held a variety of positions, including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Integrated Genetics, national director of research and development, and global head of LabCorp Clinical Trials. His research interests include Molecular Pathology and Oncology based biomarkers, and that work has resulted in the development and validation of multiple companion diagnostics and pharmacogenomic assays in clinical use today.
He holds a doctorate in genetics from Iowa State University and was an American Cancer Society postdoctoral fellow at the Waksman Institute of Microbiology at Rutgers University.Message Presenter
Bin Wu, PhD, Senior Director, Head of Translational Medicine, Agios Pharmaceuticals Inc
Dr. Wu joined Agios in January 2015. She brings over 20 years of industry experience across aspects of oncology research, translational medicine, clinical biomarkers & companion diagnostics. Highly effective at integrating scientific knowledge and cutting-edge technologies with operational excellence to enable a precision-medicine approach, Dr. Wu has supported targeted therapy clinical development and the successful approval of Ivosidenib monotherapy in both relapsed refractory and newly diagnosed AML. Prior to joining Agios, Dr. Wu held positions of increasing responsibilities at various biopharmaceutical/biotech companies, including Sanofi Oncology, Exelixis, and Chiron Corporation.
Dr. Wu holds a doctorate in cellular and molecular biology from University of Utah School of Medicine. She undertook postdoctoral studies at The Salk Institute for Biological Studies and was a recipient of the National Research Service Award from National Institute of Neurological Disorders and Stroke.Message Presenter
Who Should Attend?
Biopharmaceutical sponsors and researchers developing new therapeutics for solid tumors and hematologic malignancies.
What You Will Learn
In this webinar, attendees will learn about:
- The multi-faceted nature of cancer heterogeneity and its impact on cancer progression & persistence
- A single-cell analysis platform to detect and quantify genomic alterations
- Applications in monitoring of minimum residual disease, mutation co-occurrence and clonal evolution
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.
Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.